<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03625869</url>
  </required_header>
  <id_info>
    <org_study_id>MIR-CIP 0002</org_study_id>
    <nct_id>NCT03625869</nct_id>
  </id_info>
  <brief_title>Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction</brief_title>
  <acronym>PiCSO-AMI-I</acronym>
  <official_title>First Randomized Study of Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miracor Medical SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Miracor Medical SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess efficacy and safety of Pressure-controlled&#xD;
      intermittent Coronary Sinus Occlusion (PiCSO) therapy started post flow restoration but prior&#xD;
      to stenting during percutaneous coronary intervention (PCI) compared to standard PCI in the&#xD;
      setting of acute ST-segment elevation anterior myocardial infarction (STEMI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, randomized (1:1), controlled, study. Patients with an&#xD;
      ST-segment elevated anterior infarct eligible for PCI will be invited to participate in the&#xD;
      PiCSO-AMI-I study. After consent as per pproved ethics committee requirements, baseline&#xD;
      assessments will be performed. PCI of the culprit vessel should be performed per standard&#xD;
      practices. After blood flow restoration, the subjects meeting all inclusion and none&#xD;
      exclusion criterial will be enrolled into the study and randomized either to PiCSO Group or&#xD;
      Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be&#xD;
      cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS.&#xD;
      In the event the PiCSO Impulse Catheter cannot be placed in the CS within 30 minutes, the&#xD;
      physician should proceed with the regular PCI and the PiCSO treatment will be considered a&#xD;
      failure. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed&#xD;
      by stenting. The physician shall target a PiCSO treatment of 45 minutes (at minimum 30&#xD;
      minutes) whereas the treatment should be continued during and post stent insertion, but&#xD;
      should not exceed a maximum duration of 90 minutes. At the end of the PiCSO treatment, the&#xD;
      PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed. The patient is&#xD;
      seen for a FU visit at 5 days, 30 days, 6 months, 1 year, 2 year and 3 years post index&#xD;
      procedure. 5 days and 6 months post index the patient will get a CMR scan. At every FU visit&#xD;
      safety data and health status will be documented and quality of life questionnaire will be&#xD;
      completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective, multicenter, randomized (1:1), controlled, study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Analysis of the primary endpoint, infarct size 5-days post MI assessed by CMR, will be analyzed by an independent Corelab, blinded to the allocated treatment arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct size 5 days post MI</measure>
    <time_frame>5 days post MI</time_frame>
    <description>Difference in myocardial infarct size (extent of myocardial necrosis quantified by delayed gadolinium enhancement presented as a percentage of LV mass) between the PiCSO Group and the Control Group, assessed by CMR at 5 days post index PCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct size 6 months post MI</measure>
    <time_frame>6 months post MI</time_frame>
    <description>Myocardial infarct size (% of LV mass) assessed by CMR at 6 months post index PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MVO</measure>
    <time_frame>5 days post MI</time_frame>
    <description>Occurrence and extent of microvascular obstruction (MVO, % of LV mass) and hemorrhage assessed by CMR at 5 days post index PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF</measure>
    <time_frame>5 days and 6 months post MI</time_frame>
    <description>LVEF assessed by CMR at 5 days and 6 months post index PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVESV</measure>
    <time_frame>5 days and 6 months post MI</time_frame>
    <description>LVESV assessed by CMR at 5 days and 6 months post index PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEDV</measure>
    <time_frame>5 days and 6 months post MI</time_frame>
    <description>LVEDV assessed by CMR at 5 days and 6 months post index PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Salvage</measure>
    <time_frame>5 days and 6 months post MI</time_frame>
    <description>Myocardial Salvage Index at 5 days and 6 month post index PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST-segment resolution</measure>
    <time_frame>90 minutes</time_frame>
    <description>ST-segment resolution at 90 minutes post flow restoration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device and Procedural success, assessed as percent of subjects with successful access, delivery, and retrieval of the device and its delivery system</measure>
    <time_frame>1 day</time_frame>
    <description>Device success and procedural success rate presented as % of subjects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>STEMI</condition>
  <condition>Anterior MI</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PICSO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PiCSO</intervention_name>
    <description>After blood flow restoration, the subjects meeting all inclusion and none exclusion criterial will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes (at minimum 30 minutes) whereas the treatment should be continued during and post stent insertion, but should not exceed a maximum duration of 90 minutes. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.</description>
    <arm_group_label>PICSO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years old&#xD;
&#xD;
          2. Culprit lesion in proximal or mid LAD&#xD;
&#xD;
          3. Pre-PCI TIMI flow 0 or 1.&#xD;
&#xD;
          4. Symptoms onset time consistent with myocardial ischemia (e.g. persistent chest pain,&#xD;
             shortness of breath, nausea/vomiting, fatigue, palpitations or syncope) ≤ 12 h.&#xD;
&#xD;
          5. ECG evidence of acute anterior myocardial infarction with ST-elevation ≥ 2 mm (0.2 mV)&#xD;
             in 2 or more contiguous anterior precordial ECG leads (one of which should be V2, V3,&#xD;
             or V4) in men or ≥ 1.5 mm (0.15 mV) in women&#xD;
&#xD;
          6. Patient is deemed eligible for primary PCI&#xD;
&#xD;
          7. STEMI patients: consent as per approved national ethical committee specific&#xD;
             requirements prior to the procedure.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Implants or foreign bodies in the coronary sinus&#xD;
&#xD;
          2. Known allergy to polyurethanes, PET or stainless steel&#xD;
&#xD;
          3. Known pregnancy and breastfeeding&#xD;
&#xD;
          4. Pericardial effusion (cardiac tamponade)&#xD;
&#xD;
          5. Central hemodynamically relevant left/right shunt&#xD;
&#xD;
          6. Previous MI or CABG&#xD;
&#xD;
          7. History of stroke, TIA or reversible ischemic neurological deficit within last 6&#xD;
             months&#xD;
&#xD;
          8. Known coagulopathy&#xD;
&#xD;
          9. Need for circulatory support or pre-procedural ventilation&#xD;
&#xD;
         10. Patients with cardio-pulmonary resuscitated (CPR) cardiac arrest for more than 5&#xD;
             minutes&#xD;
&#xD;
         11. Patient not suitable for femoral vein access&#xD;
&#xD;
         12. Contraindication to cardiac magnetic resonance imaging (CMR), e.g. claustrophobia,&#xD;
             foreign body implants incompatible with CMR, gadolinium intolerance.&#xD;
&#xD;
         13. Active participation in another drug or device investigational study&#xD;
&#xD;
         14. Known severe kidney disease or on hemodialysis&#xD;
&#xD;
         15. Unconscious on presentation&#xD;
&#xD;
         16. Patients under judicial protection, legal guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Banning, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Affairs</last_name>
    <phone>+32 4 220 88 00</phone>
    <email>clinical@miracormedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jens Flensted Lassen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hôpiteaux de Bordeaux, Hôpital Haut Lévéque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Coste, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Van Belle, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Carrié, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg GmbH</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steffen Schnupp, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukas Hunziker, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>EOC Ospedale Regionale di Lugano - Civico</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Valgimigli, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Clydebank</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin Berry, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Edinburgh Royal Infirmary</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miles Behan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brompton and Harefield Hospital</name>
      <address>
        <city>Harefield</city>
        <zip>UB9 6JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Ilsley, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hopsitals</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Greenwood, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Palmer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajay Jain, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azfar Zaman, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Banning, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PiCSO</keyword>
  <keyword>PiCSO Impulse System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

